RESUMEN
BACKGROUND: The growth benefits of cotrimoxazole during early antiretroviral therapy (ART) are not well characterized. METHODS: Individuals enrolled in the Therapeutics Research, Education, and AIDS Training in Asia Pediatric HIV Observational Database were included if they started ART at ages 1 month-14 years and had both height and weight measurements available at ART initiation (baseline). Generalized estimating equations were used to identify factors associated with change in height-for-age z-score (HAZ), follow-up HAZ ≥ -2, change in weight-for-age z-score (WAZ), and follow-up WAZ ≥ -2. RESULTS: A total of 3217 children were eligible for analysis. The adjusted mean change in HAZ among cotrimoxazole and non-cotrimoxazole users did not differ significantly over the first 24 months of ART. In children who were stunted (HAZ < -2) at baseline, cotrimoxazole use was not associated with a follow-up HAZ ≥ -2. The adjusted mean change in WAZ among children with a baseline CD4 percentage (CD4%) >25% became significantly different between cotrimoxazole and non-cotrimoxazole users after 6 months of ART and remained significant after 24 months (overall P < .01). Similar changes in WAZ were observed in those with a baseline CD4% between 10% and 24% (overall P < .01). Cotrimoxazole use was not associated with a significant difference in follow-up WAZ in children with a baseline CD4% <10%. In those underweight (WAZ < -2) at baseline, cotrimoxazole use was associated with a follow-up WAZ ≥ -2 (adjusted odds ratio, 1.70 vs not using cotrimoxazole [95% confidence interval, 1.28-2.25], P < .01). This association was driven by children with a baseline CD4% ≥10%. CONCLUSIONS: Cotrimoxazole use is associated with benefits to WAZ but not HAZ during early ART in Asian children.
Asunto(s)
Antibacterianos/uso terapéutico , Fármacos Anti-VIH/uso terapéutico , Profilaxis Antibiótica , Estatura/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Infecciones por VIH/tratamiento farmacológico , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Asia , Niño , Desarrollo Infantil/efectos de los fármacos , Preescolar , Quimioterapia Combinada , Femenino , Humanos , Lactante , MasculinoRESUMEN
The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5%) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years [stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years]. In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p<0.001, > 2 years vs. no experience: OR 14.92, p<0.001), use of PI (> 2.6 years vs. no experience: OR 0.26, p<0.001), and total duration of cART (> vs. ≤ 3.8 years: OR 4.84, p<0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region.
Asunto(s)
Síndrome de Lipodistrofia Asociada a VIH/epidemiología , Síndrome de Lipodistrofia Asociada a VIH/etiología , Estavudina/efectos adversos , Adulto , Terapia Antirretroviral Altamente Activa/efectos adversos , Terapia Antirretroviral Altamente Activa/métodos , Asia/epidemiología , Pueblo Asiatico , Estudios de Cohortes , Bases de Datos Factuales , Femenino , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Prevalencia , Factores de Riesgo , Población BlancaRESUMEN
BACKGROUND: The nutritional and body shape response after the initiation of highly active antiretroviral therapy (HAART) in resource-limited environments has not been documented. In this environment, nutritional compromise is a common complication of human immunodeficiency virus (HIV) infection. METHODS: We conducted a prospective study of 190 HIV-infected patients who initiated a nevirapine-based HAART regimen. CD4+ T cell count, body weight, body mass index, anthropometry, and bioelectrical impedance data were collected prior to initiation of therapy and after 6 months of therapy. RESULTS: The mean age of participants was 35 years, 85% of participants were male, and 59% received stavudine as 1 of the nucleosides in their initial HAART regimen. The members of the cohort were malnourished before the initiation of therapy and had a mean body mass index of 20.1 (calculated as weight in kilograms divided by the square of height in meters). Overall, body weight increased a mean of 2.8 kg (range, -12.5 to 22.5 kg), and CD4+ T cell counts increased by a mean of 140 cells/mm3. Patients were stratified into those who lost weight (loss of >1 kg, 22%; n=41), those whose weight remained stable (19%; n=37), and those who gained weight (gain of >1 kg, 59%; n=112). Patients in all groups retained body shape symmetry and experienced no change in waist-to-hip ratio or regional body shape by anthropometry. CONCLUSIONS: The group that lost weight and the group whose weight remained stable experienced significant CD4+ T cell count increases at 6 months. Although the majority of HIV-infected patients who received nevirapine-based HAART gained weight, there were participants who lost weight despite initiating their first HAART therapy.
Asunto(s)
Terapia Antirretroviral Altamente Activa/efectos adversos , Peso Corporal/efectos de los fármacos , Infecciones por VIH/tratamiento farmacológico , Nevirapina/efectos adversos , Nevirapina/uso terapéutico , Adulto , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/uso terapéutico , Composición Corporal , Recuento de Linfocito CD4 , Estudios de Cohortes , Femenino , Infecciones por VIH/epidemiología , Humanos , India/epidemiología , Lamivudine/efectos adversos , Lamivudine/uso terapéutico , Masculino , Estavudina/efectos adversos , Estavudina/uso terapéutico , Zidovudina/efectos adversos , Zidovudina/uso terapéuticoRESUMEN
We analyzed final height of 273 perinatally HIV-infected Asian adolescents older than 18 years at their last clinic visit. By the World Health Organization child growth reference, 30% were stunted, but by the Thai child growth reference, 19% were stunted. Half of those who were stunted at antiretroviral therapy initiation remained stunted over time. Being male and having a low baseline height-for-age Z score of less than -1.0 were associated with low final height Z score.
Asunto(s)
Estatura , Trastornos del Crecimiento/epidemiología , Infecciones por VIH/complicaciones , Adolescente , Pueblo Asiatico , Niño , Femenino , Humanos , Masculino , Factores Sexuales , Tailandia , Adulto JovenRESUMEN
PURPOSE OF REVIEW: This review proposes to examine the role of nutrition (defined at body mass index, food security or nutrition interventions) in each of the steps of the treatment cascade for HIV. RECENT FINDINGS: Food insecurity was found to be associated with increase in risk behaviors, with decreased retention in care and with lower adherence to antiretroviral therapy; fewer studies looked at the role of baseline body weight on outcomes such as mortality. Studies of nutrition interventions had more complex outcomes but improvement in nutritional status was the outcome that was most commonly identified. SUMMARY: Nutrition has an important role to play in the current care of HIV-infected individuals and can have an impact on the treatment cascade. Food in security, which may be reversed by the provision of food, is of particular interest as studies suggest associations with multiple outcomes.
Asunto(s)
Suplementos Dietéticos , Infecciones por VIH/tratamiento farmacológico , Estado Nutricional , Abastecimiento de Alimentos , Humanos , Resultado del TratamientoRESUMEN
OBJECTIVE: To evaluate the value of time-updated weight and height in predicting clinical progression, and immunological and virological failure in children receiving combination antiretroviral therapy (cART). METHODS: We used Cox regression to analyze data of a cohort of Asian children. RESULTS: A total of 2608 children were included; median age at cART was 5.7 years. Time-updated weight for age z score < -3 was associated with mortality (P < 0.001) independent of CD4% and < -2 was associated with immunological failure (P ≤ 0.03) independent of age at cART. CONCLUSIONS: Weight monitoring provides useful data to inform clinical management of children on cART in resource-limited settings.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Estatura/fisiología , Peso Corporal/fisiología , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/fisiopatología , VIH-1/aislamiento & purificación , Adolescente , Asia , Recuento de Linfocito CD4 , Niño , Preescolar , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Infecciones por VIH/virología , Humanos , Estimación de Kaplan-Meier , Masculino , Modelos de Riesgos Proporcionales , Insuficiencia del Tratamiento , Carga ViralRESUMEN
OBJECTIVE: To describe the causes of mortality among the HIV-infected in southern India in the era of highly active antiretroviral therapy (HAART). METHODS: Analyses of this patient cohort were conducted using the YRG Centre for AIDS Research and Education HIV Natural History Observational Database. Causes of death were then individually confirmed by patient chart review. RESULTS: Sixty-nine deaths occurred within the inpatient unit; 25% were female and the median age of the 69 patients was 34 years. Over half of the patients (55%) died within three months of initiating HAART. At the time of enrollment into clinical care, the median CD4 cell count was 64 cells/microl (interquartile range (IQR) 37-134). At the time of initiating HAART, the median CD4 cell count was 58 cells/microl (IQR 31-67) for patients who died within 3 months of initiating HAART and 110 cells/microl (IQR 77-189) for patients who died more than 3 months after initiating HAART. Close to three-fourths of patients (70%) died from an AIDS-defining illness (ADI). The major ADI causes of death included Pneumocystis jiroveci pneumonia (22%), extrapulmonary tuberculosis (19%), CNS toxoplasmosis (12%), and pulmonary tuberculosis (10%). A tenth of patients died from cerebrovascular infarcts. Three patients (4%) died from non-Hodgkin lymphoma. CONCLUSIONS: AIDS-related events continue to be the major source of mortality among the HIV-infected in southern India in the era of HAART. This mortality pattern justifies increased proactive efforts to identify HIV-infected patients and initiate HAART earlier, before patients present to care with advanced immunodeficiency.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/mortalidad , Terapia Antirretroviral Altamente Activa , Causas de Muerte/tendencias , Infecciones por VIH/complicaciones , Infecciones por VIH/mortalidad , Infecciones Oportunistas Relacionadas con el SIDA/etiología , Adulto , Femenino , Infecciones por VIH/tratamiento farmacológico , Humanos , India/epidemiología , Linfoma no Hodgkin/mortalidad , Masculino , Neumonía por Pneumocystis/mortalidad , Toxoplasmosis Cerebral/mortalidad , Tuberculosis/mortalidad , Tuberculosis Pulmonar/mortalidadRESUMEN
OBJECTIVE: To describe the safe substitution with zidovudine (AZT) among South Indian HIV-infected patients who were initiated with stavudine (d4T)-containing highly active antiretroviral therapy (HAART) due to anemia. METHODS: Therapy-naïve patients initiating HAART between January 2006 and December 2007 and who had had d4T substituted for AZT at a tertiary HIV referral center in India were analyzed. RESULTS: Six hundred and nineteen patients initiated d4T-containing HAART (median CD4 110 cells/microl; median hemoglobin 10.4 g/dl) during the study period. Subsequently half of these patients substituted d4T for AZT (median CD4 350 cells/microl; median hemoglobin 12.8 g/dl). After substituting with AZT, three patients (2.7%) who substituted after less than 6 months and one patient (0.6%) who substituted at between 6 and 12 months developed anemia. Patients who substituted after less than 6 months had significantly higher median CD4 cell counts at 1-month and 6-months of follow-up than patients who substituted at between 6 and 12 months (p<0.05). Few patients (1.6%) experienced treatment failure; about a tenth of patients developed d4T-related toxicities. CONCLUSION: Few patients developed anemia (1.4%) within 6 months of substitution with AZT. In settings where tenofovir is either expensive or not available and where patients are anemic, initiating d4T followed by prompt substitution with AZT can be a safe and tolerable treatment option.
Asunto(s)
Anemia/inducido químicamente , Anemia/prevención & control , Fármacos Anti-VIH/administración & dosificación , Terapia Antirretroviral Altamente Activa , Infecciones por VIH/tratamiento farmacológico , Estavudina/efectos adversos , Zidovudina/administración & dosificación , Anemia/tratamiento farmacológico , Fármacos Anti-VIH/uso terapéutico , Esquema de Medicación , Quimioterapia Combinada , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , Humanos , India , Pobreza , Resultado del Tratamiento , Zidovudina/uso terapéuticoRESUMEN
OBJECTIVE: The role of oxidative stress in disease progression has been shown to be more complicated in HIV-infected individuals receiving highly active antiretroviral therapy (HAART) compared to those who remain treatment-naïve. This study examined the changes in the antioxidant profile of HIV-infected subjects who remained HAART-naïve due to a high CD4 cell count and HIV-negative controls, over a 12-month follow-up period at YRG CARE, a tertiary HIV referral centre in southern India. METHODS: We prospectively studied 35 HIV-infected participants (18 on d4T+3TC+EFV (stavudine+lamivudine+efavirenz), eight on AZT+3TC+EFV (zidovudine+lamivudine+efavirenz), and nine who were antiretroviral therapy-naïve) and 20 HIV-negative controls. Antioxidant profile (total antioxidant status, glutathione reductase, glutathione peroxidase, uric acid, ceruloplasmin, zinc, and albumin), CD4 cell count, plasma viral load, dietary intake, and history of smoking and alcohol use were determined at baseline and at twelve months. RESULTS: At 12 months, participants on HAART showed a significant increase in glutathione peroxidase (baseline: 1765 vs. 12 months: 2850U/l; p<0.001) and albumin (3.6 vs. 4.4g/dl; p<0.001), and a significant decrease in glutathione reductase (52.6 vs. 50.5U/l; p=0.054) and uric acid (5.4 vs. 4.8mg/dl; p=0.027) compared to baseline. Also HAART-naïve participants had a significant increase in albumin (baseline: 3.7 vs.12 months: 4.3g/dl; p=0.023) and a significant decrease in zinc levels (baseline: 79.0 vs.12 months: 74.5microg/dl; p=0.052) from baseline to 12 months. HIV-negative subjects had a significant increase in glutathione reductase at 12 months from baseline (baseline: 37 vs.12 months: 39U/l; p=0.002). No significant difference in total antioxidant status, ceruloplasmin, and zinc levels were observed in HAART-experienced subjects and negative controls over the 12-month follow-up period. CONCLUSION: This study documents changes in antioxidants over a period of time in HAART-experienced subjects in a southern India setting.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa/efectos adversos , Infecciones por VIH/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Adulto , Albúminas/efectos de los fármacos , Albúminas/metabolismo , Alquinos , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/farmacología , Antioxidantes/metabolismo , Benzoxazinas/farmacología , Benzoxazinas/uso terapéutico , Recuento de Linfocito CD4 , Ciclopropanos , Quimioterapia Combinada , Medicamentos Genéricos/efectos adversos , Medicamentos Genéricos/farmacología , Medicamentos Genéricos/uso terapéutico , Femenino , Glutatión Peroxidasa/efectos de los fármacos , Glutatión Peroxidasa/metabolismo , Glutatión Reductasa/efectos de los fármacos , Glutatión Reductasa/metabolismo , Infecciones por VIH/inmunología , Infecciones por VIH/virología , Humanos , India , Lamivudine/farmacología , Lamivudine/uso terapéutico , Masculino , Inhibidores de la Transcriptasa Inversa/efectos adversos , Inhibidores de la Transcriptasa Inversa/farmacología , Estavudina/farmacología , Estavudina/uso terapéutico , Ácido Úrico/metabolismo , Adulto Joven , Zidovudina/farmacología , Zidovudina/uso terapéuticoRESUMEN
To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). Anemia and hepatitis often occur within 12 weeks of initiating generic HAART. Frequent and early monitoring for these toxicities is warranted in developing countries where generic HAART is increasingly available.
Asunto(s)
Terapia Antirretroviral Altamente Activa/efectos adversos , Medicamentos Genéricos/efectos adversos , Infecciones por VIH/tratamiento farmacológico , Adulto , Anemia/inducido químicamente , Anemia/epidemiología , Fármacos Anti-VIH/efectos adversos , Recuento de Linfocito CD4 , Enfermedad Hepática Inducida por Sustancias y Drogas/epidemiología , Quimioterapia Combinada , Exantema/inducido químicamente , Exantema/epidemiología , Femenino , Infecciones por VIH/virología , Humanos , Incidencia , India/epidemiología , Masculino , Nevirapina/efectos adversos , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Enfermedades del Sistema Nervioso Periférico/epidemiología , Inhibidores de la Transcriptasa Inversa/efectos adversos , Estavudina/efectos adversosRESUMEN
OBJECTIVE: To describe reasons for modification and discontinuation of antiretroviral regimens in association with adverse events (AEs), treatment failure, and cost among patients in southern India. METHODS: Secular trends of patients initiating highly active antiretroviral therapy (HAART) between January 1996 and October 2004 at a tertiary HIV referral center in India were analyzed using a previously validated natural history database. RESULTS: All previously antiretroviral therapy-naive patients who initiated HAART (N = 1443) and had at least 1 follow-up visit were evaluated. The median CD4 count at the time of initiating HAART was 108 cells/microL. The most common first-line regimens were stavudine (d4T) plus lamivudine (3TC) plus nevirapine (NVP) (63%), zidovudine (AZT) plus 3TC plus NVP (19%), d4T plus 3TC plus efavirenz (EFV) (9%), and AZT plus 3TC plus EFV (4%). Twenty percent of patients modified their first-line regimen. The most common reason for modifying therapy was the development of an AE (64%), followed by cost (19%) and treatment failure (14%), with median times to modify therapy being 40, 151, and 406 days, respectively. Common AEs were itching and/or skin rash (66%), hepatotoxicity (27%), and anemia (23%). Nine percent of patients discontinued therapy entirely after a median duration of 124 days, primarily because of cost (64%). CONCLUSION: The most common reason for modifying therapy was the occurrence of AEs, whereas cost was the most common reason for discontinuing therapy. Despite increasing access to lower cost generic HAART in India, even less expensive and more tolerable first-line regimens and cost-effective treatment monitoring tools need to be introduced to achieve better treatment outcomes and access in resource-constrained settings.